NEW YORK (Reuters) Mar 14 – A former employee has accused drugmaker Warner-Lambert, acquired by Pfizer Inc. in 2000, of aggressively marketing the anticonvulsant Neurontin (gabapentin) to physicians for more than a dozen medical conditions for which it was not approved, the New York Times reported on Thursday.
David Franklin, a former research fellow at Harvard Medical School who was hired as a medical liaison by Warner-Lambert in 1996, alleges in court filings that the company was not satisfied with the limited sales potential of Neurontin.
To boost sales, the company illegally marketed Neurontin to physicians for conditions including attention deficit disorder in children, neurologic pain and bipolar disorder, Franklin said, according to the Times.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!